Hubei Goto Biopharm Co.,Ltd. (SHE:300966)

Market Cap	1.81B
Revenue (ttm)	546.75M
Net Income (ttm)	-13.94M
Shares Out	115.28M
EPS (ttm)	-0.12
PE Ratio	n/a
Forward PE	n/a
Dividend	0.02 (0.10%)
Ex-Dividend Date	n/a

Volume	2,070,300
Average Volume	2,771,723
Open	15.75
Previous Close	15.66
Day's Range	15.37 - 15.94
52-Week Range	13.04 - 23.80
Beta	0.12
RSI	46.53
Earnings Date	Apr 24, 2025

About Hubei Goto Biopharm

Hubei Goto Biopharm Co.,Ltd. engages in the research, development, production, and sale of steroid drug raw materials and intermediates in China and internationally. It offers starting materials, such as androstenedione, bisnordiol, and 9-hydroxyandrostenedione; intermediates, including sex hormone, progesterone, corticosteroid, and other pharmaceutical raw materials. The company was founded in 2006 and is based in Xiangyang, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 631
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300966

Financial Performance

In 2023, Hubei Goto Biopharm's revenue was 566.40 million, a decrease of -6.31% compared to the previous year's 604.57 million. Earnings were 23.01 million, a decrease of -42.78%.